Biotech Values

[DewDiligence]

ENTA’s $195M of regulatory milestones payments from ABBV are more than merely potential sources of cash. At this point, no serious investors can think that ABBV/ENTA’s 3-DAA regimen won’t be approved for marketing within the next year or so.